

Ravindra (Ravi) Majeti MD, PhD

Stanford University
Department of Medicine
Division of Hematology
Cancer Institute
Institute for Stem Cell Biology and Regenerative Medicine

Lokey Stem Cell Building
265 Campus Drive, G3021B
Stanford, CA 94305
(ph) 650-721-6376
rmajeti@stanford.edu
<http://majetilab.stanford.edu>

Positions, Education, and Training

Associate Professor of Medicine, Division of Hematology – Stanford University	11/1/2015-current
Assistant Professor of Medicine, Division of Hematology – Stanford University	5/01/2009-4/30/2016
Instructor in Medicine, Division of Hematology - Stanford University	2007-2009
Fellowship in Hematology - Stanford University, Stanford, CA	2004-2007
Residency in Internal Medicine - Brigham & Women's Hospital, Boston, MA	2002-2004
MD - University of California, San Francisco (UCSF), San Francisco, CA	June 2002
PhD in Biomedical Sciences - UCSF, San Francisco, CA	August 2000
AB in Biochemical Sciences - Harvard University, Cambridge, MA	June 1994

Leadership Positions

Chief, Division of Hematology – Stanford University	2017-current
Co-Director Lymphoma and Leukemia Program, Stanford Cancer Center	2014-current
Stanford Medicine Leadership Academy	2014-2015
Director, Translational Program in Hematologic Malignancies	2013-2017
Co-Director Stanford Translational Investigator Pathway, Internal Medicine Residency	2013-2017

Honors

American Society for Clinical Investigation, Member	2017
Lorie Strauss Visiting Leukemia Professor, Memorial Sloan Kettering Cancer Center	2016
Leukemia and Lymphoma Society – Scholar Award	2015
New York Stem Cell Foundation – Robertson Stem Cell Investigator	2011
Burroughs Wellcome Fund Career Award for Medical Scientists	2008
Helen Hay Whitney Fellowship (declined)	2006
Medical Student Achievement Award - American College of Rheumatology	2000
MSTP Fellowship – UCSF	1994
Summa Cum Laude - Harvard College	1994
Phi Beta Kappa - Harvard College	1994

Professional Societies, License, and Certification

American Board of Internal Medicine – Subspecialty Certification in Hematology	2007- current
American Board of Internal Medicine – Diplomate in Internal Medicine	2005
Medical Board of California – Physician and Surgeon License	2004-current
American Society of Hematology	2004-current
American Association for Cancer Research	2010-current
International Society for Stem Cell Research	2010-current
American Society of Hematology, Myeloid Neoplasia Scientific Committee	2013-current
Ad Hoc Member, Molecular and Cellular Hematology NIH Study Section	2014
Ad Hoc Member, Hematology and Vascular Biology NIH Special Study Section	2016
American Society of Hematology, Myeloid Neoplasia Scientific Committee, Vice Chair	2017
American Society of Hematology, Blood Journal Editorial Board Member	2017-current

Publications (*indicates equal authorship)

Peer-Reviewed

1. Karamitros D*, Stoilova B*, Aboukhalil Z, Hamey F, Reinisch A, Samitsch M, Quek L, Otto G, Repapi E, Doondeea J, Usukhbayar B, Calvo J, Taylor S, Goardon N, Six E, Pflumio F, Porcher C, **Majeti R**, Gottgens B, and Vyas P. *Functional and transcriptional heterogeneity of human hemopoietic lymphomyeloid progenitors at the single cell level.* Nature Immunology, 19: 85-97(2017)
2. Bak RO*, Dever DP*, Reinisch A*, Cruz Hernandez D, **Majeti R***, and Porteus MH*. *Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6.* eLife, 6; pii:e27873 (2017)
3. Reinisch A, Hernandez DC, Schallmoser K, and **Majeti R**. *Generation and use of a humanized bone-marrow-ossicle niche for hematopoietic xenotransplantation into mice.* Nature Protocols, 12: 2169-2188 (2017)
4. McKeown MR*, Corces MR*, Eaton ML*, Fiore C*, Lee E, Lopez JT, Chen MW, Cmith D, Chan SM, Koenig JL, Austgen K, Guenther MG, Orlando DA, Loven J, Fritz CC, and **Majeti R**. *Superenhancer analysis defines novel epigenomic subtypes of non-APL AML, including an RARa dependency targetable by SY-1425, a potent and selective RARa agonist.* Cancer Discovery, 7: 1136-1153 (2017)
5. Sinha S*, Thomas D*, Chan S, Gao Y, Brunen D, Torabi D, Reinisch A, Hernandez D, Chan A, Rankin EB, Bernardis R, **Majeti R***, and Dill DL*. *Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.* Nature Communications, 8: 15580 (2017)
6. Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, Esparza R, Richard C, Ramaswamy V, Remke M, Volkmer AK, Willingham S, Ponnuswami A, McCarty A, Lovelace P, Storm TA, Schubert S, Hutter G, Narayanan C, Chu P, Raabe EH, Harsh G, Taylor MD, Monje M, Cho YJ, **Majeti R**, Volkmer JP, Fisher PG, Grant G, Steinberg GK, Vogel H, Edwards M, Weissman IL, and Cheshier SH. *Disrupting the CD47-SIRPa anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.* Science Translational Medicine, 9: 381 (2017)
7. Chao MP, Gentles AJ, Chatterjee S, Lan F, Reinisch A, Corces MR, Xavy S, Shen J, Haag D, Chanda S, Sinha R, Morganti RM, Nishimura T, Ameen M, Wu H, Wernig M, Wu JC, and **Majeti R**. *Human AML-iPSCs reacquire leukemic properties after differentiation and model clonal variation of disease.* Cell Stem Cell, 20:329-344 (2016)
8. Dever DP*, Bak RO*, Reinisch A, Camarena J, Washington G, Nicolas CE, Pavel-Dinu M, Saxena N, Wilkens AB, Mantri S, Uchida N, Hendel A, Narla A, **Majeti R**, Weinberg KI, and Porteus M. *CRISPR/Cas9 beta-globin gene targeting in human hematopoietic stem cells.* Nature, 539: 384-389 (2016)
9. Matre P, Velez J, Jacamo R, Qi Y, Su X, Cai T, Chan SM, Lodi A, Sweeney SR, Ma H, Davis RE, Baran N, Haferlach T, Su X, Flores ER, Gonzalez D, Konoplev S, Samudio I, DiNardo C, **Majeti R**, Schimmer AD, Li W, Wang T, Tiziani S, and Konopleva M. *Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.* Oncotarget, 7: 79722-79735 (2016)
10. Huang M, Garcia JS, Thomas D, Zhu L, Nguyen LX, Chan SM, **Majeti R**, Medeiros BC, and Mitchell BS. *Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells.* Oncotarget, 7: 74917-74930 (2016)
11. Corces MR, Buenrostro J, Wu B, Greenside PG, Chan SM, Koenig JL, Snyder MP, Pritchard JK, Kundaje A, Greenleaf WJ, **Majeti R***, and Chang H*. *Lineage-specific and single cell chromatin accessibility charts human hematopoiesis and leukemia evolution.* Nature Genetics, 48: 1193-1203

(2016)

12. Jonas BA, Johnson C, Gratzinger D, and **Majeti R**. *Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity*. PLoS One, 11: e0159189 (2016)
13. Weiskopf K, Jahchan ND, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, Guerston H, Barkal A, Trapani F, George J, Poirier JT, Gardner EE, Miles LA, de Stanchina E, Lofgren SM, Vogel H, Winslow MM, Dive C, Thomas RK, Rudin CM, van de Rijn M, **Majeti R**, Garcia KC, Weissman IL, and Sage J. *CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer*. Journal of Clinical Investigation, 126: 2610-2620 (2016)
14. Reinisch A, Thomas D, Corces MR, Zhang X, Gratzinger D, Hong WJ, Schallmoser K, Strunk D, and **Majeti R**. *A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells*. Nature Medicine, 22: 812-821 (2016)
15. Zhu L, Li Q, Wong SH, Huang M, Klein BJ, Shen J, Ikenouye L, Onishi M, Schneidawind D, Buechele C, Hansen L, Duque-Afonso J, Zhu F, Mas Martin G, Gozani O, **Majeti R**, Kutateladze TG, and Cleary ML. *ASH1L links histone H3 lysine 36 di-methylation to MLL leukemia*. Cancer Discovery, 6: 770-783 (2016)
16. Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, Wang L, Weiskopf K, and **Majeti R**. *SIRP-a antibody fusion proteins selectively bind and eliminate dual antigen-expressing tumor cells*. Clinical Cancer Research, 22: 5109-5119 (2016)
17. Zhang M, Hutter G, Kahn SA, Azad TD, Gholamin S, Xu CY, Liu J, Achrol AS, Richard C, Sommerkamp P, Schoen MK, McCracken MN, **Majeti R**, Weissman I, Mitra SS, and Cheshier SH. *Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo*. PLoS One, 11: e0153550 (2016)
18. Mazumdar C, Shen Y, Xavy S, Zhao F, Reinisch A, Li R, Corces-Zimmerman MR, Flynn RA, Buenrostro JD, Chan SM, Thomas D, Koenig JL, Hong WJ, Chang HY, and **Majeti R**. *Leukemia-associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation*. Cell Stem Cell, 17: 675-688 (2015)
19. Jung N*, Dai B*, Gentles AJ, **Majeti R***, and Feinberg A*. *An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis*. Nat Communications, 7: 8489 (2015)
20. Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL*, and **Majeti R***. *Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential*. PLoS One, 10: e0137345 (2015)
21. Piccione EC, Juarez S, Liu J, Tseng S, Ryan C, Narayanan C, Wang L, Weiskopf K, and **Majeti R**. *A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells*. MAbs, 7: 946-956 (2015)
22. McClellan JS*, Dove CG*, Gentles AJ, Ryan CE, and **Majeti R**. *Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages*. P.N.A.S., 112: 4074-4079 (2015)
23. Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, Sinha R, Guo F, Fabionar H, Wehrman TS, Krutzik P, Demharter S, Plo, I Weissman IL, Minary P, **Majeti R**, Constantinescu SN,

- Piebler J, and Garcia KC. *Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands*. Cell, 160: 1196-1208 (2015)
24. Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, Zhao F, Medeiros BC, Tyvoll DA, and **Majeti R**. *Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia*. Nature Medicine, 21: 178-184 (2015)
 25. Sinha S, Thomas D, Yu L, Gentles AJ, Jung N, Corces-Zimmerman MR, Chan SM, Reinisch A, Feinberg AP, Dill DL*, **Majeti R***. *Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition*. Blood, 125: 316-326 (2015)
 26. Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, Chan CK, Senarath-Yapa K, Seo EY, Wearda T, Hartwig UF, Beham-Schmid C, Trajanoski S, Lin Q, Wagner W, Dullin C, Alves F, Andreeff M, Weissman IL, Longaker MT, Schallmoser K, **Majeti R**, Strunk D. *Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation*. Blood, 125: 249-260 (2015)
 27. Green MR, Vicente-Duenas C, Romero-Camarero I, Long Liu C, Dai B, Gonzalez-Herrero I, Garcia-Ramirez I, Alonso-Escudero E, Iqbal J, Chan WC, Campos-Sanchez E, Orfao A, Pintado B, Flores T, Blanco O, Jimenez R, Martinez-Climent JA, Criado FJ, Cenador MB, Zhao S, Natkunam Y, Lossos IS, **Majeti R**, Melnick A, Cobaleda C, Alizadeh AA, and Sanchez-Garcia I. *Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma*. Nat Commun, 5: 3904 (2014).
 28. Nguyen LX, Chan SM, Ngo TD, Raval A, Kim KK, **Majeti R**, and Mitchell BS. *Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells*. Blood, 124: 579-589 (2014)
 29. Lee JY, Hong W, **Majeti R**, and Stearns T. *Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms*. PLoS One, 9: e92641 (2014)
 30. Corces-Zimmerman MR, Hong W, Weissman IL, Medeiros BC, and **Majeti R**. *Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission*. P.N.A.S., 111: 2548-2553 (2014)
 31. Huang M, Thomas D, Li MX, Feng W, Chan SM, **Majeti R**, and Mitchell BS. *Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib*. Leukemia, 27: 1970-1980 (2013)
 32. Craddock C, Quek L, Goardon N, Freeman S, Siddique S, Raghavan M, Aztberger A, Schuh A, Grimwade D, Ivery A, Virgo P, Hills R, McSkeane T, Arrazi J, Knapper S, Brookes C, Davies B, Price A, Wall K, Griffiths M, Cavenagh J, **Majeti R**, Weissman I, Burnett A, and Vyas P. *Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia*. Leukemia, 27: 1028-1036 (2012)
 33. Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL*, Quake SR*, and **Majeti R***. *Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia*. Science Translational Medicine, 4: 149ra118 (2012)
 34. Ochsenreither S, **Majeti R**, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, Hudecek M, Akatsuka Y, Weissman IL, and Greenberg P. *Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen*. Blood, 119: 5492-5501 (2012)
 35. Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, Liu J, **Majeti R**, West RB, Fletcher JA, Beck AH, Weissman IL, and van de Rijn M. *Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma*. P.N.A.S., 109: 6656-

- 6661 (2012)
36. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PO, Steinberg GK, Li G, So SK, **Majeti R**, Harsh GR van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, and Weissman IL. *The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors.* P.N.A.S., 109: 6662-6667 (2012)
 37. McClellan JS, Kohrt HE, Coutre SS, Gotlib JR, **Majeti R**, Alizadeh AA, and Medeiros BC. *Treatment advances have not improved the early death rate in acute promyelocytic leukemia.* Haematologica, 97: 133-136 (2012)
 38. Chao MP, Tang C, Pachynski RK, Chin R, **Majeti R***, and Weissman IL*. *Extra-nodal dissemination of non-Hodgkin's lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.* Blood, 118: 4890-4901 (2011)
 39. Gibbs KD, Gilbert PM, Sachs K, Zhao F, Blau HM, Weissman IL, Nolan GP*, and **Majeti R***. *Single cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments.* Blood, 117: 4226-4233 (2011)
 40. Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, and **Majeti R**. *Prospective separation of normal and leukemia stem cells based on differential expression of TIM3, a human AML stem cell marker.* P.N.A.S., 108: 5009-5014 (2011)
 41. Gentles AJ, Plevritis SK, **Majeti R***, and Alizadeh AA*. *Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.* JAMA, 304: 2706-15 (2010)
 42. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, **Majeti R***, and Weissman IL*. *Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47.* Sci Transl Med, 2: 63ra94 (2010)
 43. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL*, and **Majeti R***. *Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.* Cancer Res, 1:1374-84 (2011)
 44. Kohrt HE, Patel S, Ho M, Owen T, Pollyea DA, **Majeti R**, Gotlib J, Coutre S, Liedtke M, Berube C, Alizadeh AA, and Medeiros BC. *Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.* Am J Hematol, 85: 877-81 (2010)
 45. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL*, and **Majeti R***. *Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin Lymphoma.* Cell, 142: 699-713 (2010)
 46. Medeiros BC, Kohrt HE, Arber DA, Bangs CD, Cherry AM, **Majeti R**, Kogel KE, Azar CA, Patel S, and Alizadeh AA. *Immunophenotypic features of acute myeloid leukemia with inv(3)(q21;q26.2)/t(3;3)(q21;q26.2).* Leukemia Research, 34: 594-597 (2010)
 47. **Majeti R***, Chao MP*, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, van Rooijen N, and Weissman IL. *CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.* Cell, 138: 286-299 (2009)

48. Jaiswal S, Jamieson CHM, Pang WW, Park, CY, Chao MP, **Majeti R**, Traver D, van Rooijen N, and Weissman IL. *CD47 is up-regulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.* Cell, 138: 271-285 (2009)
49. **Majeti R***, Becker MW*, Tian Q*, Lee M, Yan X, Liu R, Chiang J, Clarke MF, Hood, L, and Weissman IL. *Dysregulated gene expression networks in human acute myelogenous leukemia stem cells.* P.N.A.S., 106: 3396-3401 (2009)
50. Ooi AGL, Karsunky H, **Majeti R**, Butz S, Vestweber D, Ishida T, Quertermous T, Weissman IL, and Forsberg EC. *The adhesion molecule ESAM1 is a novel hematopoietic stem cell marker.* Stem Cells, 27: 653-661 (2009)
51. Park CY*, **Majeti R***, and Weissman IL. *In vivo evaluation of human hematopoiesis through xenotransplantation of purified hematopoietic stem cells from umbilical cord blood.* Nature Protocols, 3: 1932-1940 (2008)
52. **Majeti R***, Park CY*, and Weissman IL. *Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood.* Cell Stem Cell, 1:635-645 (2007)
53. Hermiston ML, Tan AL, Gupta VA, **Majeti R**, and Weiss A. *The juxtamembrane wedge negatively regulates CD45 function in B cells.* Immunity, 23: 635-647 (2005)
54. Baker JE, **Majeti R**, Tangye SG, and Weiss A. *Protein tyrosine phosphatase CD148-mediated inhibition of T cell receptor signal transduction occurs through the reduction of LAT and PLC-g phosphorylation.* Mol. Cell. Bio., 21: 2393-2403 (2001)
55. **Majeti R**, Xu Z, Parslow TG, Olson JL, Daikh DI, Killeen N, and Weiss A. *An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity.* Cell, 103: 1059-1070 (2000)
56. Lagunoff M, **Majeti R**, Weiss A, and Ganem D. *Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus.* P.N.A.S., 96: 5704-5709 (1999)
57. **Majeti R**, Bilwes AM, Noel JP, Hunter T, and Weiss A. *Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge.* Science, 279: 88-91 (1998)

Peer Reviewed Reviews

1. Corces MR, Chang, HY, and **Majeti R**. *Pre-leukemic hematopoietic stem cells in human acute myeloid leukemia.* Frontiers in Oncology, 7: 263 (2017)
2. Thomas D and **Majeti R**. *Biology and relevance of human acute myeloid leukemia stem cells.* Blood, 129:1577-1585 (2017)
3. Mazumdar C and **Majeti R**. *The role of mutations in the cohesin complex in acute myeloid leukemia.* Int J Hematol, 105:31-36 (2017)
4. Sykes SM, Kokkaliaris KD, Milsom MD, Levine RL, and **Majeti R**. *Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia.* Exp Hematology, 43: 989-992 (2015)
5. Reinisch A, Chan SM, Thomas D, and **Majeti R**. *Biology and clinical relevance of acute myeloid leukemia stem cells.* Semin Hematol, 52: 150-164 (2015)
6. **Majeti R**. *Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia.* Best Pract Res Clin Haematol, 27: 229-234 (2014)

7. Corces-Zimmerman MR and **Majeti R**. *Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis*. Leukemia, 28: 2276-82. (2014)
8. Chan SM and **Majeti R**. *Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia*. International Journal of Hematology, 98: 648-657 (2013)
9. Jan M and **Majeti R**. *Clonal evolution of acute leukemia genomes*. Oncogene, 10: 135-140 (2012)
10. Chao MP, Weissman IL*, and **Majeti R***. *The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications*. Current Opinion in Immunology, 24: 225-32 (2012)
11. Chao MP, **Majeti R***, and Weissman IL*. *Programmed cell removal: a new obstacle in the road to developing cancer*. Nature Reviews Cancer, 12: 58-67 (2011)
12. **Majeti R**. *Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells*. Oncogene, 30:1009-19 (2011)
13. Jaiswal S, Chao MP, **Majeti R**, and Weissman IL. *Macrophages as mediators of tumor immunosurveillance*. Trends Immunol, 31: 212-219 (2010)
14. Hermiston ML, Xu Z, **Majeti R**, and Weiss A. *Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases*. J. Clin. Invest., 109: 9-14 (2002)
15. **Majeti R** and Weiss A. *Regulatory mechanisms for receptor protein tyrosine phosphatases*. Chemical Reviews, 101: 2441-2448 (2001)

Case Reports

1. Chao MP, Hong J, Kunder C, Lester L, Schrier SL, and **Majeti R**. *Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss Syndrome responsive to eculizumab and rituximab*. Am J Hematol, 90: 78-81 (2015)

Non-Peer Reviewed Commentaries

1. Thomas D and **Majeti R**. *Optimizing next-generation AML therapy: activity of mutant IDH2 inhibitor AG-221 in preclinical models*. Cancer Discovery, 7: 459-461 (2017)
2. Reinisch A and **Majeti R**. *Sticking it to the niche: CD98 mediates critical adhesive signals in AML*. Cancer Cell, 14: 662-664 (2016)
3. Thomas D and **Majeti R**. *Burning Fat Fuels Leukemic Stem Cell Heterogeneity*. Cell Stem Cell, 7: 1-2 (2016)
4. McClellan JS and **Majeti R**. *The cancer stem cell model: B cell acute lymphoblastic leukaemia breaks the mould*. EMBO Mol Med, 5: 7-9 (2013)
5. Alizadeh AA and **Majeti R**. *Surprise! HSC are aberrant in chronic lymphocytic leukemia*. Cancer Cell, 20: 135-6 (2011)
6. **Majeti R** and Weissman IL. *Human Acute Myelogenous Leukemia Stem Cells Revisited: There's More Than Meets the Eye*. Cancer Cell, 19: 9-10 (2011)
7. Diehn, M and **Majeti R**. *Metastatic cancer stem cells: an opportunity for improving cancer treatment?* Cell Stem Cell, 6: 502-503 (2010)

Abstracts

1. Thomas D, Sinha S, Chan SM, Wu M, Torabi D, Peltz G, Gao Y, Dill D*, and **Majeti R***. *Isocitrate Dehydrogenase 1 Mutant Cancers are Metabolically Vulnerable to Inhibition of Acetyl-CoA Carboxylase Via a 2-Hydroxyglutarate Independent Mechanism*. Blood (ASH Annual Meeting Abstracts) 128:1054 (2016) (Selected for Oral Presentation)
2. Chao MP, Gentles A, Chatterjee S, Reinisch A, Corces MR, Shen J, Rachel M, Sinha R, Haag D, Wernig M, Wu J, and **Majeti R**. *Pluripotent Reprogramming of Human AML Resets Leukemic Behavior and Models Therapeutic Targeting of Subclones*. Blood (ASH Annual Meeting Abstracts) 128:575 (2016) (Selected for Oral Presentation)
3. Mazumdar C, Shen Y, Xavy S, Zhao F, Reinisch A, Li R, Corces-Zimmerman MR, Buenrostro J, Chan SM, Thomas D, Koenig J, Hong WJ, Chang H, and **Majeti R**. *Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation*. Blood (ASH Annual Meeting Abstracts) 126:841 (2015) (Selected for Oral Presentation)
4. Sinha S, Thomas D, Chan S, Gao Y, Jansen R, **Majeti R**, and Dill D. *Boolean Implication Mining for Synthetic Lethal Interactions in AML Identifies Acetyl-CoA Carboxylase as a Synthetic Lethal Partner of the IDH1 Mutation*. Blood (ASH Annual Meeting Abstracts) 126:1404 (2015)
5. Thomas D, Sinha S, Yu L, Jung N, Dai B, Gentles A, Feinberg AP, Dill D, and **Majeti R**. *Mutation in Wilms' Tumor 1 Induces DNA Hypermethylation of PRC2 Targets, Blocks Myelomonocytic Differentiation, and Defines a Novel Subtype of AML Responsive to EZH2 Inhibition*. Blood (ASH Annual Meeting Abstracts) 124:780 (2014) (Selected for Oral Presentation)
6. Reinisch A, Gratzinger D, Hong WJ, **Majeti R**. *A Novel Humanized Bone Marrow Niche Xenotransplantation Model Allows Superior Engraftment of Human Normal and Malignant Hematopoietic Cells and Reveals Myelofibrosis-Initiating Cells in the HSC Compartment*. Blood (ASH Annual Meeting Abstracts) 124:349 (2014) (Selected for Oral Presentation)
7. Corces-Zimmerman MR, Eaton M, Lopez J, Ke N, Fritz C, Olson E, **Majeti R**, and Loven J. *Discovery and Characterization of Super-Enhancer-Associated Dependencies in Acute Myeloid Leukemia*. Blood (ASH Annual Meeting Abstracts) 124:3539 (2014)
8. Chan SM, Thomas D, Medeiros BC, and **Majeti R**. *Isocitrate Dehydrogenase Mutations Induce BCL-2 Dependence in Acute Myeloid Leukemia through Inhibition of Cytochrome C Oxidase Function*. Blood (ASH Annual Meeting Abstracts) 124:615 (2014) (Selected for oral presentation)
9. Matre P, Shariati M, Velez J, Qi Y, Konoplev S, Su X, DiNardo CD, Daver N, **Majeti R**, Andreeff M, Chan SM, and Konopleva M. *Efficacy of Novel Glutaminase Inhibitor CB-839 in Acute Myeloid Leukemia*. Blood (ASH Annual Meeting Abstracts) 124:3763 (2014)
10. Mazumdar C, Li R, Buenrostro J, Chang H, and **Majeti R**. *Cohesin Complex Mutations Impair Differentiation of Human Hematopoietic Stem and Progenitor Cells*. Blood (ASH Annual Meeting Abstracts) 124:4785 (2014)
11. Reinisch A and **Majeti R**. *An in vivo model of primary myelofibrosis using a humanized bone marrow niche reveals disease-initiating cells in the CD34+/CD38-/CD90+ hematopoietic compartment*. International Society for Experimental Hematology, 2014 Annual Meeting. (Selected for oral presentation).
12. Sinha S, Thomas D, Gentles A, Yu L, Jung N, Feinberg A, Dill D, and **Majeti R**. *Integrative Analysis of TCGA Data Reveals Wilms' Tumor 1 Mutation is a Driver of DNA Methylation in Acute Myeloid Leukemia*. TCGA Third Annual Scientific Symposium. (Selected for oral presentation)

13. Sinha S, Thomas D, Yu L, Jung N, Gentles A, Feinberg A, Dill D, and **Majeti R.** *Wilms' Tumour Mutation is a Driver of DNA Hypermethylation in Acute Myeloid Leukemia.* Keystone Symposia - Cancer Epigenetics Q1 #3037. (Selected for oral presentation)
14. Thomas D, Sinha S, Yu L, Jung N., Gentles A, Feinberg A, Dill D, and **Majeti R.** *Boolean Implications Identify Wilms' Tumour 1 Mutation as a Driver of DNA Hypermethylation in Acute Myeloid Leukemia.* New Directions in Leukemia Research (NDLR 2014); Noosa, Queensland, Australia. (Selected for oral presentation)
15. Sinha S, Thomas D, Yu L, Jung N, Gentles A, Feinberg A, Dill D, and **Majeti R.** *Wilms' Tumour 1 Mutation is a Driver of DNA Hypermethylation in Acute Myeloid Leukemia.* Biomedical Computation at Stanford 14th Annual Symposium (BACTS 2014)
16. Corces-Zimmerman MR, Hong WJ, and **Majeti R.** *Mutations in Genes Regulating the Epigenome Occur Early During the Evolution of Human AML and Persist During Remission.* Keystone Symposia - Cancer Epigenetics Q1, 1047 (2014)
17. McClellan JS, Gentles AJ, Ryan CE, and **Majeti R.** *Transdifferentiation of Human Philadelphia Chromosome-Positive B Cell Acute Lymphoblastic Leukemia Cells into Non-Leukemic Macrophages.* Blood (ASH Annual Meeting Abstracts) 122:1430 (2013)
18. Chan SM, Medeiros BC, and **Majeti R.** *BCL-2 Inhibition as a Synthetic Lethal Approach to Target Isocitrate Dehydrogenase Mutations in Acute Myeloid Leukemia Stem Cells.* Blood (ASH Annual Meeting Abstracts) 122:885 (2013) (Selected for oral presentation)
19. Nguyen LT, Huang M, Chan SM, **Majeti R,** and Mitchell BS. *Activation Of Akt Enhances Ribosomal RNA Synthesis In AML Cells Through a Novel Isoform Of TIF-1A and Inhibition Of Filamin A Cleavage.* Blood (ASH Annual Meeting Abstracts) 122:1266 (2013)
20. Jan M, Synder TM, Corces-Zimmerman MR, Weissman IL, Quake SR, and **Majeti R.** *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML.* American Association of Cancer Research, 103rd Annual Meeting (2012)
21. Jan M, Synder TM, Corces-Zimmerman MR, Weissman IL, Quake SR, and **Majeti R.** *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML.* Blood (ASH Annual Meeting Abstracts) 118:4 (2011) (Selected for oral presentation)
22. Craddock C, Goardon N, Quek L, Freeman S, Siddique S, Raghavan M, Schuh A, Grimwade D, Hills RK, Brookes C, Griffiths M, Cavenagh JD, **Majeti R,** Weissman IL, Burnett AK, and Vyas P. *Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia.* Blood (ASH Annual Meeting Abstracts) 118:638 (2011)
23. Jan M, Alizadeh AA, Chao MP, Cha AC, Sahoo D, Weissman IL, and **Majeti R.** *TIM-3 Is a Novel Human Acute Myeloid Leukemia Marker that Enables the Prospective Separation of Normal and Leukemia Stem Cells.* ISSCR 8th Annual Meeting (2010)
24. Chao MP, Alizadeh AA, Tang CZ, Myklebust JH, Varghese B, Jan M, Levy R, Weissman IL, and **Majeti R.** *Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts.* Blood (ASH Annual Meeting Abstracts) 114:2716 (2009)
25. Gibbs K, Gilbert P, Weissman IL, Blau HM, Nolan GP, and **Majeti R.** *Single Cell Phospho-Flow Analysis of Cytokine Stimulation in Human Hematopoietic Progenitors Reveals That G-CSF Acts Directly On Human Hematopoietic Stem Cells.* Blood (ASH Annual Meeting Abstracts) 114:3617 (2009)

26. Alizadeh AA, McClellan JS, Gotlib JR, Coutre S, **Majeti R**, Kohrt HE, and Medeiros BC. *Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported*. Blood (ASH Annual Meeting Abstracts) 114: 1015 (2009)
27. Kohrt HE, Patel S, Ho M, Owen T, **Majeti R**, Gotlib JR, Coutre S, Medeiros BC, and Alizadeh AA. *Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS)*. Blood (ASH Annual Meeting Abstracts) 114: 1617 (2009)

Oral Presentations

1. 21st International RUNX Conference 11/13/2017
Title: *Characterization of Pre-Leukemic HSPCs with Engineered FPD/AML RUNX1 Mutations*
2. University of California, Irvine – MSTP Retreat 10/27/2017
Title: *Stem Cells in Human AML*
3. 4th International Conference on AML, European School of Hematology 10/6/2017
Title: *Stem Cells in Human AML*
4. 4th International Conference on AML, European School of Hematology 10/6/2017
Title: *Pre-Clinical Development of a Humanized Anti-CD47 Antibody*
5. FASEB Meeting, Hematologic Malignancies 7/25/2017
Title: *Stem Cells in Human AML*
6. Pharmaceutical and BioScience Society, Minisymposium 6/28/2017
Title: *Pre-Clinical Development of a Humanized Anti-CD47 Antibody*
7. Acute Leukemias XVI, Munich 2/19/2017
Title: *Epigenetics in Human AML: Leukemia-Associated Cohesin Mutations and AML-Derived iPSCs*
8. Keystone Meeting, Hematopoiesis 2/4/2017
Title: *Stem Cells in Human AML*
9. 7th Biennial Workshop, Clinical Translation of Epigenetics in Cancer Therapy 1/15/2017
Title: *Pluripotent Reprogramming of Human AML Resets Leukemic Behavior and Models Therapeutic Targeting of Subclones*
10. American Society of Hematology, 2016 Annual Meeting Scientific Session 12/3/2016
Title: *Chromatin Accessibility Charts Human Hematopoiesis and AML Evolution*
11. American Society of Hematology, 2016 Annual Meeting Workshop 12/2/2016
Title: *CD47/SIRPalpha Directed Therapy to Reverse Macrophage Inhibition*
12. New York Stem Cell Foundation, 11th Annual Meeting 10/26/2016
Title: *Pre-Clinical Development of a Humanized Anti-CD47 Antibody*
13. 91st Stem Cell Biology and Regenerative Medicine Forum, University of Tokyo 10/17/2016
Title: *Stem Cells in Human AML*
14. Japanese Society of Hematology, 78th Annual Meeting 10/13/2016
Title: *Pre-Leukemic Hematopoietic Stem Cells in Human AML*
15. Hematological Malignancies: From Mechanisms to Therapy, Milan, Italy 3/10/2016
Title: *Pre-Leukemic Hematopoietic Stem Cells in Human AML*
16. 5th International Workshop on Humanized Mice, Zurich, Switzerland 1/28/2016
Title: *A Novel Humanized Bone Marrow Niche Xenotransplantation Model Allows Superior Engraftment of Human Normal and Malignant Hematopoiesis*
17. American Society of Hematology, 2015 Annual Meeting Scientific Program 12/5/2015
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
18. 8th International Conference on WT1 in Human Neoplasia 11/19/2015

- Title: *Mutant WT1 is Associated with DNA Hypermethylation of PRC2 Targets in AML and Responds to EZH2 Inhibition*
19. Society of Hematologic Oncology, 2015 Annual Meeting 9/19/2015
Houston, Texas
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
 20. ESH International Conference on AML 9/11/2015
Budapest, Hungary
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
 21. ESH International Conference on AML 9/10/2015
Budapest, Hungary
Title: *IDH1/2 Mutations Induce BCL-2 Dependence in Acute Myeloid Leukemia*
 22. Working Conference on the Classification and Nomenclature of Clonal Conditions 8/21/2015
Vienna, Austria
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
 23. European Hematology Association, 2015 Annual Meeting, Plenary Session 6/14/2015
Vienna, Austria
Title: *Tracking and Targeting Leukemia Stem Cells*
 24. International Society for Experimental Hematology - Webinar 6/03/2015
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
 25. 7th Biennial Workshop, Clinical Translation of Epigenetics in Cancer Therapy 1/17/2015
St. Augustine, Florida
Title: *Mutant WT1 is Associated with DNA Hypermethylation of PRC2 Targets in AML and Responds to EZH2 Inhibition*
 26. 2014 World Alliance Forum in San Francisco on Stem Cell Research and Regenerative Medicine 11/06/2014
San Francisco, California
Title: *Pre-Clinical Development of a Humanized Anti-CD47 Antibody Targeting AML Stem Cells*
 27. American Association for Cancer Research, Hematologic Malignancies: Translating Discoveries to Novel Therapies 9/21/2014
Philadelphia, Pennsylvania
Title: *Pre-Clinical Development of a Humanized Anti-CD47 Antibody Targeting AML Stem Cells*
 28. International Society for Experimental Hematology, Annual Meeting 8/23/2014
Montreal, Canada
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
 29. Leukemia and Lymphoma Society, Annual Scientific Meeting 5/05/2014
Washington D.C.
Title: *A Bispecific Antibody Targeting CD47 and CD20 Selectively Binds and Eliminates Dual Antigen Expressing NHL Cells*
 30. Acute Leukemia Forum 2014 4/25/2014
San Francisco, California
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
 31. 8th Sino-US Symposium on Medicine in the 21st Century 11/16/2013
Shanghai, China
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Malignancies*

32. Nature Biotechnology SciCafe
San Francisco, California
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies* 11/07/2013
33. 2013 Annual Meeting, Japanese Society of Hematology
Sapporo, Japan
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML* 10/08/2013
34. 2nd International Michelangelo Conference
Milan, Italy
Title: *Antibody Therapy Targeting CD47* 7/05/2013
35. 1st Annual, Shanghai International Workshop on Stem Cells and Cancer
Shanghai, China
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML* 4/19/2013
36. 2013 Bone Marrow Transplant Tandem Meetings
Salt Lake City, Utah
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML* 2/14/2013
37. Charles Rodolphe Brupbacher Symposium
Zurich, Switzerland
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies* 1/31/2013
38. American Society of Hematology, Myeloid Workshop
Atlanta, Georgia
Title: *Pre-Clinical Development of a Humanized Anti-CD47 Antibody for the Treatment of AML* 12/07/2012
39. Regenerative Medicine Seminar Series, Stanford University
Stanford, California
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML* 11/29/2012
40. German Cancer Research Center (DKFZ), 2nd Symposium, Targeted Cancer Therapy
Heidelberg, Germany
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies* 11/20/2012
41. German Society of Hematology and Oncology (DGHO), Annual Meeting – Plenary Session
Stuttgart, Germany
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML* 10/20/2012
42. New York Stem Cell Foundation, Annual Meeting
New York, New York
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML* 10/12/2012
43. American Society of Clinical Oncology, Annual Meeting
Chicago, Illinois
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML* 6/04/2012
44. Integrative Cancer Biology Program, NCI Steering Committee Meeting
Burlingame, California
Title: *Identification of Key Drivers of Human AML Stem Cell Pathogenesis* 5/08/2012
45. Center for Cancer Systems Biology, 2nd Annual Symposium, Stanford University
Stanford, California
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML* 5/07/2012

46. American Association for Cancer Research, 103rd Annual Meeting
Chicago, Illinois 4/03/2012
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
47. American Society of Hematology, 53rd Annual Meeting – Plenary Session
San Diego, California 12/09/2011
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
48. University of Sao Paulo Conference on Stem Cells
Sao Paulo, Brazil 10/24/2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*
49. 20th Anniversary Symposium of GRAN
Tokyo, Japan 10/01/2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*
50. Stem Cell Research Symposium, Kyushu University
Fukuoka, Japan 9/29/2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Malignancies*
51. 2nd Meeting, Experimental Hematology, CEINGE
Naples, Italy 6/29/2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*
52. European Hematology Association, 16th Annual Meeting
London, England 6/12/2011
Title: *Monoclonal Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells*
53. Center for Cancer Systems Biology, 1st Annual Symposium, Stanford University
Stanford, California 5/03/2011
Title: *Computational and Functional Approaches to Investigation of Leukemia Stem Cells in AML*
54. American Association for Cancer Research, 102nd Annual Meeting
Washington D.C. 4/02/2011
Title: *Therapeutic Targeting of Cancer Stem Cell Survival Mechanisms*
55. American Association for Cancer Research, 102nd Annual Meeting
Washington D.C. 4/02/2011
Title: *Isolation of Normal Hematopoietic Stem Cells and Acute Myeloid Leukemia Stem Cells*
56. CIRM - India Institute for Stem Cell Biology (inSTEM) Collaborative Meeting
Bangalore, India 3/21/2011
Title: *Clinical Significance and Prospective Separation of Leukemia Stem Cells in AML*
57. City of Hope, Innovative Partnerships: Bringing Stem Cell Discoveries to the Clinic
City of Hope, California 11/18/2010
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*
58. NHLBI, Progenitor Cell Biology Consortium Meeting
Seattle, Washington 10/21/2010
Title: *Single Cell Phospho-Flow Cytometry Reveals Human HSC Respond Directly to Numerous Cytokines*
59. Japanese Society of Hematology, 72nd Annual Meeting
Yokohama, Japan 9/24/2010

Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*

60. Intl Conference, Stem Cells: the Diverging Goals of Regenerative Medicine and Oncology
Rome, Italy 7/02/2010
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*
61. American Association for Cancer Research, 101st Annual Meeting
Washington D.C. 4/17/2010
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*
62. 17th International Molecular Medicine Tri-Conference
San Francisco, California 2/08/2010
Title: *CD47: An Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells*
63. International Society for Stem Cell Research, 8th Annual Meeting
San Francisco, California 6/18/2010
Title: *TIM-3 Is a Novel Human Acute Myeloid Leukemia Marker that Enables the Prospective Separation of Normal and Leukemia Stem Cells*
64. IBC 20th Annual International Conference, Antibody Engineering
San Diego, California 12/08/2009
Title: *Blocking monoclonal antibodies directed against CD47 preferentially enable phagocytosis and elimination of human acute myeloid leukemia stem cells*
65. AACR-NCI-EORTC Conference, Molecular Targets and Cancer Therapeutics
Boston, Massachusetts 11/18/2009
Title: *CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*
66. Keystone Meeting, Antibodies as Drugs
Whistler, British Columbia, Canada 3/29/2009
Title: *Blocking monoclonal antibodies directed against CD47 preferentially enable phagocytosis and elimination of human acute myeloid leukemia stem cells*
67. American Society of Hematology, 50th Annual Meeting
San Francisco, California 12/07/2008
Title: *CD47 is an independent prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*
68. Gordon Research Conference, Stem Cells and Cancer
Big Sky Resort, Montana 9/12/2007
Title: *Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood*
69. American College of Rheumatology, 64th Annual Meeting, Plenary Session 2000
Title: *An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity*
70. Keystone Meeting, Signaling 2000 1998
Title: *Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge*

Invited Seminars

1. Genentech Safety Science Retreat 2018
Title: *AML and Development of a Humanized Anti-CD47 Antibody*
2. Sanford Burnam Institute, San Diego 2018
Title: *Stem Cells in Human AML*
3. University of Toronto 2017
Title: *Stem Cells in Human AML*
4. Fox Chase Cancer Center, Philadelphia 2017
Title: *Stem Cells in Human AML*
5. San Raffaele Scientific Institute, Milan 2017
Title: *Stem Cells in Human AML*
6. British Columbia Cancer Research GrasPods Keynote Address 2017
Title: *Stem Cells in Human AML*
7. Northwestern Medical School, Department of Biochemistry and Molecular Genetics Seminar 2017
Title: *Stem Cells in Human AML*
8. Fudan Medical School, Shanghai, China 2016
Title: *Stem Cells in Human AML*
9. UCSD, Genomics, Bioinformatics, and Systems Biology Colloquium 2016
Title: *Stem Cells in Human AML*
10. City of Hope, Leukemia Seminar Series 2016
Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
11. Memorial Sloan Kettering Cancer Center, Medicine Grand Rounds 2016
Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
12. University of Chicago, Cancer Center Seminar Series 2016
Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
13. Agios Pharmaceuticals, Cambridge, MA 2015
Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
14. Dana Farber Cancer Institute, BMT Grand Rounds 2015
Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
15. Cleveland Clinic, Stem Cell Institute 2015
Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
16. MD Anderson Cancer Center, Leukemia Grand Rounds 2014
Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
17. Albert Einstein School of Medicine – Stem Cell Institute 2013
Title: *AML Stem Cells: Isolation, Clinical Significance, and Therapeutic Targeting*
18. University of California, San Francisco – Cancer Center 2013
Title: *AML Stem Cells: Isolation, Clinical Significance, and Therapeutic Targeting*

19. University of Texas, Southwestern – Children’s Research Institute 2012
Title: *AML Stem Cells: Isolation, Clinical Significance, and Therapeutic Targeting*
20. PACTTE/NHLBI – Webinar 2012
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
21. Agilent Technologies, Santa Clara, California 2012
Title: *Characterization of Normal HSC and AML Stem Cells*
22. Epply Institute, University of Nebraska – Omaha, Cancer Short Course 2012
Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
23. American Association of Clinical Chemistry, Southern California Section 2012
Title: *Clinical Significance, Isolation, and Targeting of Leukemia Stem Cells in AML*
24. Chinese American Biopharmaceutical Society, Foster City, California 2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
25. Memorial Sloan Kettering Cancer Center, New York, New York 2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
26. Pfizer (Rinat), South San Francisco, California 2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
27. LSU Cancer Center, New Orleans, Louisiana 2010
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
28. MD Anderson Cancer Center, Houston, Texas 2010
Title: *CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*
29. Weatherall Institute of Molecular Medicine, University of Oxford, United Kingdom 2009
Title: *CD47 is an independent prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*
30. Genentech, Inc., South San Francisco, California 2009
Title: *CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*